Coherus BioSciences, Inc.
High concentration formulations of adalimumab
Last updated:
Abstract:
The present invention relates to aqueous pharmaceutical compositions comprising a high concentration (i.e., greater than 50 milligrams per milliliter) of adalimumab (including antibody proteins considered or intended as "biosimilar" or "bio-better" variants of commercially available adalimumab) suitable for long-term storage, and methods of manufacture of the compositions; methods of their administration; and articles containing the same.
Status:
Grant
Type:
Utility
Filling date:
28 Oct 2016
Issue date:
25 Jan 2022